FMR LLC Acquires New Stake in Bicara Therapeutics Inc.

FMR LLC Acquires New Stake in Bicara Therapeutics Inc.

FMR LLC, a leading investment firm, has acquired a new stake in Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of fibrotic diseases. The investment will support Bicara's ongoing clinical development programs and pipeline expansion.

Strategic Investment for Bicara's Fibrosis Programs

Bicara's lead product candidate, BIC210, is a first-in-class, oral small molecule that targets the TGF-beta signaling pathway, a key driver of fibrosis. BIC210 has shown promising results in Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and is currently in Phase 3 development.

FMR's investment will enable Bicara to accelerate the development of BIC210 and expand its pipeline of fibrosis therapies. Bicara plans to initiate additional clinical trials for BIC210 in other fibrotic indications, such as liver fibrosis and kidney fibrosis.

FMR's Commitment to Healthcare Innovation

FMR's investment in Bicara Therapeutics reflects its commitment to supporting innovative healthcare companies that are developing transformative therapies for unmet medical needs. FMR has a long history of investing in healthcare and has a deep understanding of the challenges and opportunities in the industry.

The acquisition of a new stake in Bicara Therapeutics Inc. aligns with FMR's investment strategy of supporting companies with the potential to make a significant impact on patient care. Bicara's pipeline of fibrosis therapies has the potential to address a significant unmet medical need and improve the lives of patients.

About FMR LLC

FMR LLC is a leading investment firm with a diverse portfolio of investments across private equity, public equity, and real estate. FMR has a long history of investing in healthcare and has a deep understanding of the industry's challenges and opportunities.

About Bicara Therapeutics Inc.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of fibrotic diseases. Bicara's lead product candidate, BIC210, is a first-in-class, oral small molecule that targets the TGF-beta signaling pathway, a key driver of fibrosis.